1366 related articles for article (PubMed ID: 18353307)
1. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
[TBL] [Abstract][Full Text] [Related]
4. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
Wang HY; Friedman E; Olmstead MC; Burns LH
Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
[TBL] [Abstract][Full Text] [Related]
5. Effect of endothelin-A receptor antagonist on mu, delta and kappa opioid receptor-mediated antinociception in mice.
Bhalla S; Zhang Z; Patterson N; Gulati A
Eur J Pharmacol; 2010 Jun; 635(1-3):62-71. PubMed ID: 20303944
[TBL] [Abstract][Full Text] [Related]
6. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
7. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
Baker AK; Meert TF
J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
[TBL] [Abstract][Full Text] [Related]
8. Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands.
Zhu J; Luo LY; Li JG; Chen C; Liu-Chen LY
J Pharmacol Exp Ther; 1997 Aug; 282(2):676-84. PubMed ID: 9262330
[TBL] [Abstract][Full Text] [Related]
9. Novel κ-opioid receptor agonist MB-1C-OH produces potent analgesia with less depression and sedation.
Zhang LS; Wang J; Chen JC; Tao YM; Wang YH; Xu XJ; Chen J; Xu YG; Xi T; Hu XW; Wang YJ; Liu JG
Acta Pharmacol Sin; 2015 May; 36(5):565-71. PubMed ID: 25816912
[TBL] [Abstract][Full Text] [Related]
10. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice.
Ward SJ; Takemori AE
J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119
[TBL] [Abstract][Full Text] [Related]
11. Analgesic activity and pharmacological characterization of N-[1-phenylpyrazol-3-yl]-N-[1-(2-phenethyl)-4-piperidyl] propenamide, a new opioid agonist acting peripherally.
Goicoechea C; Sánchez E; Cano C; Jagerovic N; Martín MI
Eur J Pharmacol; 2008 Oct; 595(1-3):22-9. PubMed ID: 18706410
[TBL] [Abstract][Full Text] [Related]
12. Functional interaction among opioid receptor types: up-regulation of mu- and delta-opioid receptor functions after repeated stimulation of kappa-opioid receptors.
Khotib J; Narita M; Suzuki M; Yajima Y; Suzuki T
Neuropharmacology; 2004 Mar; 46(4):531-40. PubMed ID: 14975677
[TBL] [Abstract][Full Text] [Related]
13. Chronic muscle pain induced by repeated acid Injection is reversed by spinally administered mu- and delta-, but not kappa-, opioid receptor agonists.
Sluka KA; Rohlwing JJ; Bussey RA; Eikenberry SA; Wilken JM
J Pharmacol Exp Ther; 2002 Sep; 302(3):1146-50. PubMed ID: 12183674
[TBL] [Abstract][Full Text] [Related]
14. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
[TBL] [Abstract][Full Text] [Related]
15. Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity.
DeHaven-Hudkins DL; Burgos LC; Cassel JA; Daubert JD; DeHaven RN; Mansson E; Nagasaka H; Yu G; Yaksh T
J Pharmacol Exp Ther; 1999 Apr; 289(1):494-502. PubMed ID: 10087042
[TBL] [Abstract][Full Text] [Related]
16. mu- but not delta- and kappa-opioid receptors in the ventrolateral orbital cortex mediate opioid-induced antiallodynia in a rat neuropathic pain model.
Zhao M; Wang JY; Jia H; Tang JS
Brain Res; 2006 Mar; 1076(1):68-77. PubMed ID: 16476416
[TBL] [Abstract][Full Text] [Related]
17. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
18. The roles of different subtypes of opioid receptors in mediating the nucleus submedius opioid-evoked antiallodynia in a neuropathic pain model of rats.
Wang JY; Zhao M; Yuan YK; Fan GX; Jia H; Tang JS
Neuroscience; 2006; 138(4):1319-27. PubMed ID: 16472929
[TBL] [Abstract][Full Text] [Related]
19. Stimulation of mu and delta opioid receptors induces hyperalgesia while stimulation of kappa receptors induces antinociception in the hot plate test in the naked mole-rat (Heterocephalus glaber).
Towett PK; Kanui TI; Juma FD
Brain Res Bull; 2006 Dec; 71(1-3):60-8. PubMed ID: 17113929
[TBL] [Abstract][Full Text] [Related]
20. JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependence.
Codd EE; Carson JR; Colburn RW; Stone DJ; Van Besien CR; Zhang SP; Wade PR; Gallantine EL; Meert TF; Molino L; Pullan S; Razler CM; Dax SL; Flores CM
J Pharmacol Exp Ther; 2009 Apr; 329(1):241-51. PubMed ID: 19151246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
